March 8 (Reuters) - Bavarian Nordic A/S:
* BAVARIAN NORDIC ANNOUNCES PHASE 2 TRIAL INVESTIGATING COMBINATION OF ITS IMMUNOTHERAPY CV301 AND NIVOLUMAB IN MICROSATELLITE STABLE COLORECTAL CANCER
* BAVARIAN NORDIC A/S - CO, BRISTOL-MYERS SQUIBB AGREE TO SUPPLY CLINICAL MATERIAL FOR TRIAL
* BAVARIAN NORDIC A/S - PHASE 2 RANDOMIZED TRIAL WILL ENROLL UP TO 74 PATIENTS Source text for Eikon: Further company coverage: